Mainz Biomed N.V.
QUCY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for QUCY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QUCY
Mainz Biomed N.V. is a molecular genetics diagnostic company specializing in early detection of colorectal cancer, with a lead product in regulatory approval pathways and a history of recurring losses and going concern risks.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Mainz Biomed N.V..
Mainz Biomed N.V. is a molecular genetics diagnostic company specializing in early detection of colorectal cancer, with a lead product in regulatory approval pathways and a history of recurring losses and going concern risks.
- Mainz Biomed develops and commercializes in-vitro diagnostic tests for early cancer detection, with a principal product seeking regulatory approval in certain jurisdictions [sec · filed 2025-03-31].
- As of June 30, 2025, the company reported cash and equivalents of $13.4 million, net income of -$11.0 million, and shareholders' equity of $2.6 million [sec].
- The company has an accumulated deficit of $91.0 million as of December 31, 2024, and negative cash flows from operating activities of $17.1 million for the year ended December 31, 2024 [sec · filed 2025-03-31].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, relying on future debt and equity financings to fund operations [sec · filed 2025-03-31].
What works
- The company has demonstrated an ability to raise capital, raising $16.9 million in net proceeds during 2024 through a convertible note and ordinary share sales [sec · filed 2025-03-31].
- Mainz Biomed has access to additional financing through a Controlled Equity Offering and a Pre-Paid Advance Agreement, providing flexibility to fund operations [sec · filed 2025-03-31].
- The company is focused on a high-demand area—early detection of colorectal cancer—with potential for significant market adoption if regulatory approval is obtained [sec · filed 2025-03-31].
What to weigh
- The company has recurring losses and an accumulated deficit of $91.0 million as of December 31, 2024, with negative cash flows from operations [sec · filed 2025-03-31].
- Management has identified substantial doubt about the company's ability to continue as a going concern, dependent on securing additional funding [sec · filed 2025-03-31].
- Operating expenses and capital requirements are expected to increase significantly as the company expands commercialization and R&D, putting further pressure on cash reserves [sec · filed 2025-03-31].
- The company's ability to raise funds on reasonable terms is uncertain, and failure to obtain funding could force delays or elimination of key programs [sec · filed 2025-03-31].
From the filings
Quoted directly from source documents.
The company has substantial doubt about its ability to continue as a going concern.
“substantial doubt about our ability to continue as a going concern.”
SEC filings · March 31, 2025
Accumulated deficit reached $91.0 million as of December 31, 2024.
“accumulated deficit totaling $91.0 million”
SEC filings · March 31, 2025
The company raised $16.9 million in net proceeds during 2024.
“the Company raised $16.9 million of net proceeds from the issuance of a convertible note and through the sales of ordinary shares.”
SEC filings · March 31, 2025
Negative cash flows from operating activities were $17.1 million for the year ended December 31, 2024.
“negative cash flows used in operating activities of $17.1 million as of and for the year ended December 31, 2024”
SEC filings · March 31, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has substantial doubt about the company's ability to continue as a going concern [sec · filed 2025-03-31].
- Recurring losses and high burn — The company has an accumulated deficit of $91.0M and negative operating cash flows of $17.1M as of Dec 31, 2024 [sec · filed 2025-03-31].
- Dependence on future financing — The company relies on future debt/equity financings to fund operations; failure could delay or eliminate R&D and commercialization [sec · filed 2025-03-31].
- Regulatory approval risk — The principal product requires regulatory approval in certain jurisdictions, which is uncertain and could be delayed [sec · filed 2025-03-31].
What to watch
- Ability to secure additional financing through equity offerings, debt, or strategic alliances to fund operations and avoid going concern [sec · filed 2025-03-31].
- Progress of regulatory approval for the principal colorectal cancer detection test in target jurisdictions [sec · filed 2025-03-31].
- Trend in operating expenses and cash burn rate as the company expands commercialization and R&D activities [sec · filed 2025-03-31].
- Any updates on the company's accumulated deficit and net loss trajectory in future financial reports [sec · filed 2025-03-31].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run Mainz Biomed N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mainz Biomed N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
6.0 months
D/E 0.15 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$62K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 64,267 | $30K |
| susquehanna international group, llp | 18,517 | $9K |
| jane street group, llc | 16,093 | $8K |
| harbour investments, inc. | 15,730 | $7K |
| two sigma securities, llc | 12,814 | $6K |
| provenance wealth advisors, llc | 1,171 | $555 |
| bnp paribas financial markets | 600 | $284 |
| nfsg corp | 500 | $237 |
| highmark wealth management llc | 200 | $94 |
| morgan stanley | 189 | $90 |
Showing top 10 of 13 institutional holders of Mainz Biomed N.V.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 8.5%
- Days to cover
- 0.8
- Shares short
- 960,587
- Daily short volume (May 8, 2026)
- 53.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QUCY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mainz Biomed N.V.?
Mainz Biomed N.V. is a molecular genetics diagnostic company specializing in early detection of colorectal cancer, with a lead product in regulatory approval pathways and a history of recurring losses and going concern risks.
What is Mainz Biomed N.V.'s lead drug candidate?
Mainz Biomed N.V.'s most advanced tracked candidate is pancalert (Preclinical) for Pancreatic cancer.
Who is the CEO of Mainz Biomed N.V.?
Mr. David Elliot Lazar is the chief executive officer of Mainz Biomed N.V. (QUCY).
Where is Mainz Biomed N.V. headquartered?
Mainz Biomed N.V. (QUCY) is headquartered in Mainz, Germany.
What therapeutic areas does Mainz Biomed N.V. focus on?
Mainz Biomed N.V. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.